This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
Annals of Hematology Open Access 01 July 2020
-
Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells
Frontiers of Medicine Open Access 24 July 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Lyon, France, 2008.
Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121: 2253–2263.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321–1325.
Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316–1320.
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116–120.
Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011; 25: 726–729.
Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879–3884.
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–185.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298–303.
Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830–837.
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398–1403.
Gebauer N, Bernard V, Feller AC, Merz H . ID3 mutations are recurrent events in double-hit B-cell lymphomas. Anticancer Res 2013; 33: 4771–4778.
Robbiani DF, Nussenzweig MC . Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013; 8: 79–103.
Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011; 6: e28585.
Vaidya R, Witzig TE . Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol 2014; 25: 2124–2133.
Acknowledgements
We wish to thank Heike Brückner, Eva Bachmann and Tina Grieb for their excellent technical support. This study was supported by the German Ministry for Education and Science (BMBF) in the framework of the ICGC MMML-Seq (01KU1002A-J) Network and by the Robert-Bosch-Stiftung, Stuttgart, Germany.
Author Contributions
SM, GO and AR designed the research, prepared the figures and wrote the paper. SM, SW, TN, MR, AS and EB performed the experiments. SM, JP and AR analyzed and interpreted the data. AR, GO, MR, EG and SM reviewed and classified the cases.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Momose, S., Weißbach, S., Pischimarov, J. et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 29, 1789–1791 (2015). https://doi.org/10.1038/leu.2015.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.34
This article is cited by
-
Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma
Virchows Archiv (2023)
-
The “Burkitt-like” immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS
Virchows Archiv (2021)
-
Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
Annals of Hematology (2020)
-
Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells
Frontiers of Medicine (2018)
-
Double-Hit Large B Cell Lymphoma
Current Oncology Reports (2017)